MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
3.930
-0.050
-1.26%
Closed 19:55 07/11 EDT
OPEN
3.980
PREV CLOSE
3.980
HIGH
4.079
LOW
3.910
VOLUME
2.73M
TURNOVER
0
52 WEEK HIGH
4.079
52 WEEK LOW
0.9228
MARKET CAP
1.03B
P/E (TTM)
-18.2706
1D
5D
1M
3M
1Y
5Y
1D
Core CPI In Focus With JPMorgan, Goldman, Netflix Set To Report Earnings
Seeking Alpha · 1d ago
Catalyst Watch: Bank earnings rush, OPEC report, Tesla EVs get Grok, and Superman at the box office
Seeking Alpha · 2d ago
Weekly Report: what happened at AKBA last week (0630-0704)?
Weekly Report · 07/07 10:29
Weekly Report: what happened at AKBA last week (0623-0627)?
Weekly Report · 06/30 10:33
Weekly Report: what happened at AKBA last week (0616-0620)?
Weekly Report · 06/23 10:28
Weekly Report: what happened at AKBA last week (0609-0613)?
Weekly Report · 06/16 10:33
Akebia Therapeutics Approves Stock Plan Amendment at Meeting
TipRanks · 06/13 11:47
Weekly Report: what happened at AKBA last week (0602-0606)?
Weekly Report · 06/09 10:34
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.